scholarly journals Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma

2017 ◽  
Vol 6 (11) ◽  
pp. 2507-2514 ◽  
Author(s):  
Tzu-Hua Chen-Liang ◽  
Taida Martín-Santos ◽  
Andrés Jerez ◽  
Guillermo Rodríguez-García ◽  
Leonor Senent ◽  
...  
2016 ◽  
Vol 27 (6) ◽  
pp. 1095-1099 ◽  
Author(s):  
M. Alzahrani ◽  
T.C. El-Galaly ◽  
M. Hutchings ◽  
J.W. Hansen ◽  
A. Loft ◽  
...  

Author(s):  
Ryogo Minamimoto ◽  
Luis Fayad ◽  
Julie Vose ◽  
Jane Meza ◽  
Ranjana Advani ◽  
...  

Abstract Purpose To determine whether interim 3′-deoxy-3′-[18F]fluorothymidine (iFLT) PET/CT is a superior predictor of progression-free survival (PFS) compared with interim 18F-fluorodeoxyglucose (iFDG) PET/CT in patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH). Methods Ninety-two prospectively enrolled patients with DLBCL underwent both FLT-PET/CT and FDG-PET/CT 18–24 days after two cycles of R-CHOP/R-EPOCH. Deauville-criteria, PERCIST1.0, standardized uptake value (SUV), total lesion glycolysis (TLG), and metabolic tumor volume were used to interpret iFDG-PET/CT while dichotomous visual interpretation was used to interpret iFLT-PET/CT and the results were compared with the 3- and 5-year PFS. Results iFLT-PET/CT was negative in 67 (73%) and positive in 25 (27%) patients. iFDG-PET/CT by Deauville criteria was negative (Deauville scores [DS] of 1–3) in 53 (58%) and positive (DS = 4–5) in 39 (42%) patients. Of the 67 iFLT-PET/CT-negative patients, 7 (10.4%) progressed at a median of 14.1 months whereas 14/25 (56.0%) iFLT-PET/CT-positive patients progressed at a median of 7.8 months (P < .0001). Of the 53 Deauville-negative patients, 9 (17.0%) progressed at a median of 14.1 months whereas 12/39 (30.8%) Deauville-positive patients progressed at a median of 5.6 months (P = .11). In multivariate analysis, including iFLT-PET/CT, PERCIST, interim TLG, and interim SUVmax, only iFLT-PET/CT was an independent predictor for 3- and 5-year PFS (P < .0001 and P = .001, respectively). Conclusions In patients with DLBCL given R-CHOP/R-EPOCH, iFLT-PET/CT is a superior independent predictor of outcome compared with iFDG-PET/CT.


2020 ◽  
Vol 14 ◽  
pp. 117955492095309
Author(s):  
Ahmad Al-Sabbagh ◽  
Feryal Ibrahim ◽  
Lajos Szabados ◽  
Dina S Soliman ◽  
Ruba Y Taha ◽  
...  

Introduction: In the era of routine use of positron emission tomography/computed tomography (PET/CT) for staging, it is not yet clear whether PET/CT can replace bone marrow biopsy for the assessment of bone marrow involvement in large B-cell lymphoma. Objectives: To compare the clinical utility of bone marrow biopsy and PET/CT scanning in the staging of large B-cell lymphoma. Methods: This was a retrospective analysis of all patients who presented to single center over a 4-year period with large B-cell lymphoma who had concurrent PET/CT and bone marrow biopsy performed in the assessment and staging of the lymphoma. Results: Out of 89 patients, 24 had bone marrow involvement either by PET/CT, by bone marrow biopsy, or by both. Bone marrow biopsy identified 12 patients (sensitivity 50%, specificity 100%, negative predictive value 84%), whereas PET/CT identified 23 patients (sensitivity 96%, specificity 100%, negative predictive value 98%). No patients were upstaged by the bone marrow biopsy result, and no patients had their treatment plan changed based on the bone marrow biopsy result. Conclusion: The results show that PET-CT is more sensitive and has better negative predictive value than bone marrow biopsy. This suggests that PET-CT could replace bone marrow biopsy in detecting bone marrow involvement for staging of large B-cell lymphoma.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5403-5403
Author(s):  
Yusuke Saiki ◽  
Naoto Tomita ◽  
Akiko Uchida ◽  
Satoshi Yokoi ◽  
Yuji Nishio ◽  
...  

Abstract Background: Initial staging by positron emission tomography/computed tomography (PET/CT) is recommended for lymphoma of fluorodeoxyglucose (FDG)-avid histology, such as diffuse large B-cell lymphoma (DLBCL). Although both PET/CT and bone marrow biopsy (BMB) are usually performed to determine the bone marrow involvement in DLBCL, whether PET/CT alone is sufficient remains controversial. While previous reports discussing this point have used data based on medical records, here we performed a systematic review of untreated DLBCL patients, for whom a radiologist and a hematopathologist separately performed blind reviews. Methods: The subjects had DLBCL diagnosed between 2008 and 2017 for which both PET/CT and BMB were performed for staging before initiation of treatment. We excluded cases in which BMB specimens were qualitatively and/or quantitatively insufficient to determine the presence or absence of bone marrow involvement. To exclude follicular lymphoma, we did not include patients whose diagnostic specimens of lymphoma included any degree of nodular growth pattern. All PET/CT scans were performed in a single institution. In PET/CT, cases with score 4 or 5 in the Deauville criteria in bone marrow were classified as positive. In the review of BMB, we used both hematoxylin-eosin staining and CD20 immunostaining specimens in all cases to determine the involvement. We treated the presence of bone marrow involvement by BMB as a reference, and the involvement type was classified as either concordant or discordant pattern. Survival curves were compared by the log-rank test. A P-value less than 0.05 was considered to indicate a significant difference. Results: The study included 87 untreated patients with DLBCL (82 DLBCL, NOS; 3 intravascular large B-cell lymphoma; and 2 primary mediastinal large B-cell lymphoma), comprising 46 males and 41 females. The median age at the time of diagnosis was 71 (range, 19 to 87 years). The number of positive cases in PET/CT and BMB was 17 (20%) and 24 (28%), respectively (Table). Nine (10%) cases had both positive results. Among BMB-positive cases, there were18 concordant and 6 discordant involvements. When considering BMB results as a reference, PET/CT showed 38% sensitivity and 87% for specificity. The positive and negative predictive values were 53% and 79%, respectively. In 61 patients initially treated with R-CHOP, there was no significant difference in progression-free survival (PFS) between positive and negative cases in PET/CT (P = 0.16) , but PFS was significantly worse for BMB-positive cases than BMB-negative cases (P = 0.03). Conclusion: BMB is still mandatory in patients with untreated DLBCL and predicts outcome in the era of PET/CT. Routine CD20 immunostaining might be helpful in detecting lymphoma involvement in BMB specimens. Table. Table. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3871-3871
Author(s):  
Sara Alonso ◽  
Miguel Alcoceba ◽  
Oscar Blanco ◽  
Julio Davila ◽  
Juan Carlos Caballero ◽  
...  

Abstract INTRODUCTION: In the rituximab era, the prognostic influence of bone marrow (BM) infiltration in patients with diffuse large B-cell lymphoma (DLBCL) has been hardly studied. In this retrospective observational study, we aim to investigate the prognostic influence of concordant and discordant BM infiltration in patients with histological diagnosis of DLBCL. In addition, we analyzed the possible clonal relationship between BM and lymph node tumor cells in the cases with discordant histology. PATIENTS AND METHODS: All patients diagnosed of DLBCL in our center from January 1, 1999 were included in the study. Histological BM infiltration pattern was classified as concordant (DLBCL infiltration) or discordant (small or low-grade B-cell lymphoma) based on the diagnostic reports from the Pathology department. All cases were reviewed for this purpose by an expert pathologist. To further characterize the discordant cases, flow cytometry (FCM) reports of BM infiltration were reviewed. In the discordant cases, the clonal IGH rearrangement was studied in both BM and lymphadenopathy, by amplification of the VDJ genes as recommended in the BIOMED-2 protocol. For survival analysis, only patients treated with R-CHOP or similar were included. RESULTS: 236 patients diagnosed of DLBCL were included in the study; of them, 31 (13%) had concordant histological BM infiltration and 18 (7.6%) discordant. Phenotypic characterization by FCM of the discordant cases was heterogeneous: chronic lymphocytic leukemia (N = 2), follicular lymphoma (N = 5), marginal zone lymphoma (N = 2), non-specific phenotype (N = 5) or non-infiltration (N = 2). Clonality studies were performed in the discordant cases. Good quality DNA was obtained in 17 out of 18 patients. We confirmed the same clone in both BM and lymphadenopathy in 12 patients (70%); different clones were observed in two, and a polyclonal pattern was obtained in the remaining three patients. Survival analyzes were conducted only in the 186 patients treated with R-CHOP or similar. With a median follow up of 58 (1-135) months, PFS was significantly worse in patients with concordant (35% at 5 years, p = 0.001) or discordant (35% at 5 years, p = 0.04) histology, compared to patients without infiltration (64% at 5 years) (Figure 1). OS was significantly lower in patients with concordant histology (53% at 5 years, p = 0.05), whereas there was no significant difference between patients with discordant infiltration (62% at 5 years, p = 0.8) and non-affected BM (75% at 5 years). In the multivariate analysis, concordant BM infiltration (HR = 2.25, 95% CI 1.2 to 4.3, p = 0.01) had a negative influence on PFS (but not on OS), independently of the age, ECOG and LDH, while discordant histology was close to statistical significance (RR = 2; 95% CI 0.95 to 3, p = 0.1) CONCLUSIONS: Our results indicate that BM infiltration, both concordant and discordant, is associated with a lower PFS in DLBCL patients treated with R-CHOP or similar. Cases with discordant BM infiltration have a very heterogeneous phenotype, but we found a clonal relationship between the two different histologies in a high proportion of cases, indicating a probable histologic transformation from a low-grade lymphoma. Further studies are needed to determine the sequence of biological events that might be involved in this transformation. Figure 1. Progression free survival (PFS) according to the concordant or discordant histology of the BM Figure 1. Progression free survival (PFS) according to the concordant or discordant histology of the BM Disclosures No relevant conflicts of interest to declare.


PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0170299 ◽  
Author(s):  
Fadi El Karak ◽  
Ibrahim R. Bou-Orm ◽  
Marwan Ghosn ◽  
Joseph Kattan ◽  
Fadi Farhat ◽  
...  

2012 ◽  
Vol 54 (1) ◽  
pp. 83-89 ◽  
Author(s):  
Tanin Intragumtornchai ◽  
Udomsak Bunworasate ◽  
Noppadol Siritanaratkul ◽  
Archrob Khuhapinant ◽  
Weerasak Nawarawong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document